Development and Validation of a Digital Pain-Reduction Kit for Musculoskeletal Injuries
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03187132 |
Recruitment Status :
Completed
First Posted : June 14, 2017
Last Update Posted : July 21, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain, Acute Pain, Chronic | Device: Digital Pain Reduction Kit Device: Active Control | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 245 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Development and Validation of a Digital Pain-Reduction Kit for Musculoskeletal Injuries |
Actual Study Start Date : | April 3, 2018 |
Actual Primary Completion Date : | May 20, 2020 |
Actual Study Completion Date : | May 20, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Digital Pain Reduction Kit
Participants in the experimental arm will be assigned the digital pain reduction kit consisting of a transcutaneous electrical nerve stimulation unit to be used as needed and a virtual reality headset to be used as needed or at least once a day. Remote clinical support is provided for patients who volunteer information to be viewed by clinicians.
|
Device: Digital Pain Reduction Kit
A two-component intervention consisting of (1) virtual reality, experiences lasting 3-30 minutes used to distract individuals from pain and to teach skills related to chronic pain; (2) TENS unit, used to reduce acute localized pain. |
Active Comparator: Active Control
Participants in the active control arm will receive standard of care as provided by their physician in addition to a transcutaneous electrical nerve stimulation unit.
|
Device: Active Control
An active control TENS unit used to reduce acute localized pain. |
- Physical Function [ Time Frame: 60 days ]Participants will complete weekly surveys (PROMIS® PF short-form) of self-reported physical function.
- Pain Interference [ Time Frame: 60 days ]Participants will complete weekly surveys (PROMIS® Pain Interference) of self-reported pain interference.
- Work Productivity [ Time Frame: 60 days ]Participants will complete the WPAI:LB assessing work absenteeism and presenteeism.
- Satisfaction with Pain Treatment and Healthcare [ Time Frame: 60 days ]Investigators will assess satisfaction with healthcare in participants using a validated instruments.
- Opioid Use [ Time Frame: 60 days ]Investigators will examine pre and post prescription history for opioids using 90 Morphine Milligram Equivalents.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, age 18 or older
- Seeking care for a musculoskeletal injury
- Experiencing pain greater than 3 out of 10 on a visual analog scale
- English or Spanish speaking
- Owns a compatible Android or iOS smartphone device (excluding tablets)
Exclusion Criteria:
- Unable to understand the goals of the study due to cognitive difficulty
- Use of a cardiac pacemaker, implanted defibrillator, or other implanted metallic or electronic device or high-frequency surgical equipment. (contraindication for TENS units)
- Pregnant (contraindication for TENS unit)
- Current diagnosis of epilepsy, dementia, or other neurological disease that may prevent use of VR hardware or software
- Hypersensitivity to flashing light or motion
- Injury to the eyes, face, neck, or arms that prevents comfortable use of VR hardware or software, or safe use of other study hardware (e.g., open sores, wounds, or skin rash on face)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03187132
United States, California | |
Cedars-Sinai Medical Center | |
Los Angeles, California, United States, 90048 |
Responsible Party: | Brennan Spiegel, Director, Health Services Research, Cedars-Sinai Medical Center |
ClinicalTrials.gov Identifier: | NCT03187132 |
Other Study ID Numbers: |
Pro00049015 |
First Posted: | June 14, 2017 Key Record Dates |
Last Update Posted: | July 21, 2020 |
Last Verified: | July 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
virtual reality transcutaneous electrical nerve stimulation analgesia |
Acute Pain Chronic Pain Pain Neurologic Manifestations |